ResMed Inc (RMD)
Gross profit margin
| Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit (ttm) | US$ in thousands | 3,054,972 | 2,939,167 | 2,854,336 | 2,749,995 | 2,632,836 | 2,545,957 | 2,482,132 | 2,414,913 | 2,355,663 | 2,260,783 | 2,134,228 | 2,058,831 | 2,024,310 | 1,992,500 | 1,948,561 | 1,906,726 | 1,839,098 | 1,797,774 | 1,800,178 | 1,764,825 |
| Revenue (ttm) | US$ in thousands | 5,146,330 | 5,021,540 | 4,926,780 | 4,807,490 | 4,546,017 | 4,444,877 | 4,364,797 | 4,235,737 | 4,222,994 | 4,015,671 | 3,763,271 | 3,624,405 | 3,578,126 | 3,539,492 | 3,443,759 | 3,348,896 | 3,196,825 | 3,091,065 | 3,091,753 | 3,027,899 |
| Gross profit margin | 59.36% | 58.53% | 57.94% | 57.20% | 57.92% | 57.28% | 56.87% | 57.01% | 55.78% | 56.30% | 56.71% | 56.80% | 56.57% | 56.29% | 56.58% | 56.94% | 57.53% | 58.16% | 58.23% | 58.29% |
June 30, 2025 calculation
Gross profit margin = Gross profit (ttm) ÷ Revenue (ttm)
= $3,054,972K ÷ $5,146,330K
= 59.36%
The gross profit margin of ResMed Inc. exhibits a generally stable trend over the analyzed period, with slight fluctuations. Starting at approximately 58.29% at the end of September 2020, the margin demonstrated marginal declines, reaching a low of around 55.78% as of June 2023. This downward trend suggests a slight compression in gross profitability during that period, potentially attributable to increasing cost pressures or changes in sales mix.
However, subsequent data indicates a modest recovery, with the margin rising back to approximately 57.92% by June 2024. Notably, the gross profit margin demonstrates an overall upward trajectory in the most recent periods, reaching about 59.36% by June 2025. This improvement could reflect enhancements in operational efficiency, favorable pricing strategies, or cost management initiatives.
Overall, the gross profit margin remains relatively high and consistent, averaging above 56%, which underscores ResMed’s ability to maintain solid core profitability levels. The observed fluctuations align with typical industry dynamics, but the recent upward trend suggests a positive outlook for sustained gross profitability.
Peer comparison
Jun 30, 2025